Jeremy Coller

Gateway Foundation Announces New President & CEO

Retrieved on: 
Thursday, January 5, 2023
Government, United States Public Health Service, Upstate New York, College of William & Mary, Martin J. Whitman School of Management, Jeremy Coller, Interim, National Council, Omnes, City, Lach, Patient, Hotel manager, Mental, State university system, Health, Helio, Syracuse University, Management, Medicine, Gateway

CHICAGO, Jan. 5, 2023 /PRNewswire/ -- Illinois' largest and longest running addiction treatment non-profit, Gateway Foundation, announces Jeremy Klemanski as the organization's next President and Chief Executive Officer effective January 3, 2023. Klemanski will be joining Interim CEO Marc Turner who will stay on the Executive Team.

Key Points: 
  • CHICAGO, Jan. 5, 2023 /PRNewswire/ -- Illinois' largest and longest running addiction treatment non-profit, Gateway Foundation, announces Jeremy Klemanski as the organization's next President and Chief Executive Officer effective January 3, 2023.
  • Arla Lach, Chair of the Gateway Foundation Board of Directors, states, "Our hiring committee undertook an intense, nationwide search to find Gateway Foundation's next leader.
  • The board unanimously agrees that Jeremy's impressive 20+ year track record will propel Gateway Foundation forward - through treatment innovation and internal strategic growth."
  • I'm dedicated to helping all people on a path to improved health and recovery," states Jeremy Klemanski, newly appointed President and CEO of Gateway Foundation.

Strong IP, hundreds of patents secure future growth for Lleida.net

Retrieved on: 
Monday, December 19, 2022
Acquisition, R, BME, Telecommunication, D, OTCQX, Family, Lleida, LLN, Saas, Environment, Face, BLS digital signature, EIDAS, Euronext Growth, Union, BME Growth, EPA, Certification, IP, Growth, Research, Patent, SMS, Jeremy Coller, Software as a service, COVID-19, Intellectual property, Fine chemical, 3D printing, Software, Video game, Pharmaceutical industry, Food delivery, Bank, Airline, Security (finance), Mobile phone

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- A recent study drafted by Coller IP a Mathys Squire company, has valued Lleida.net's SaaS IP portfolio at as much as EUR14.1 million, a conservative valuation of a single family of the company's key intangible assets. 

Key Points: 
  • Lleida.net (OTCQX:LLEIF) (EPA:ALLLN) (BME:LLN) is a sophisticated technology company that has built its business on strong intellectual property.
  • The company's family of patents represents an important benefit for clients, stakeholders and investors and secures the future development for the medium and long term.
  • The multiple layers of protection that these patents give to the company's intellectual property assure future growth and stability.
  • The hundreds of patents granted to the company can be grouped into different patent families covering different business lines.

Strong IP, hundreds of patents secure future growth for Lleida.net

Retrieved on: 
Monday, December 19, 2022
Acquisition, R, BME, Telecommunication, D, OTCQX, Family, Lleida, LLN, Saas, Environment, Face, BLS digital signature, EIDAS, Euronext Growth, Union, BME Growth, EPA, Certification, IP, Growth, Research, Patent, SMS, Jeremy Coller, Software as a service, COVID-19, Intellectual property, Fine chemical, 3D printing, Software, Video game, Pharmaceutical industry, Food delivery, Bank, Airline, Security (finance), Mobile phone

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- A recent study drafted by Coller IP a Mathys Squire company, has valued Lleida.net's SaaS IP portfolio at as much as EUR14.1 million, a conservative valuation of a single family of the company's key intangible assets. 

Key Points: 
  • Lleida.net (OTCQX:LLEIF) (EPA:ALLLN) (BME:LLN) is a sophisticated technology company that has built its business on strong intellectual property.
  • The company's family of patents represents an important benefit for clients, stakeholders and investors and secures the future development for the medium and long term.
  • The multiple layers of protection that these patents give to the company's intellectual property assure future growth and stability.
  • The hundreds of patents granted to the company can be grouped into different patent families covering different business lines.

COP15 ‘Paris Agreement for Nature’ Will Increase Pressure on Global Meat and Dairy Producers

Retrieved on: 
Tuesday, December 6, 2022
Environmental, Social and Governance (ESG), Retail, Other Professional Services, Sustainability, Finance, Professional Services, Supply Chain Management, Other Natural Resources, Environment, Environmental Issues, Environmental Health, Other Retail, Agriculture, Natural Resources, Supermarket, Food, Beverage, Biodiversity, Water, United Nations, Fresh water, JBS, CIO, Food, Farm, Environment, COP27, Nitrogen, Egg, ESG, Sunner (surname), FAIRR, Climate, Aquaculture, Nutrient, Meat, Phosphorus, Tyson, Food and Agriculture Organization, Nature, First Nations in Ontario, Global biodiversity, Jeremy Coller, WH Group, River, Farmer, Coller Capital, Risk, Animal husbandry, Agriculture, COP15, Index

The world will gather in Montreal tomorrow to discuss a Paris Agreement for Nature (COP15) including a set of proposed targets to halt and reverse global biodiversity loss.

Key Points: 
  • The world will gather in Montreal tomorrow to discuss a Paris Agreement for Nature (COP15) including a set of proposed targets to halt and reverse global biodiversity loss.
  • However, new data from FAIRR today shows the worlds biggest meat and dairy producers are currently unprepared to meet targets expected in such a deal.
  • Jeremy Coller, Chair of FAIRR Initiative and CIO of Coller Capital, said,
    From rainforests to rivers, meat & dairy producers are failing to manage their biodiversity impacts.
  • Investors are focused on material financial risks for companies, and a global agreement on nature at COP15 would see the intensive animal agriculture industry face increased regulatory, legal, tax and reputational risks.

COP15 ‘Paris Agreement for Nature’ Will Increase Pressure on Global Meat and Dairy Producers

Retrieved on: 
Tuesday, December 6, 2022
Environmental Policy, Environmental Issues, Other Natural Resources, Sustainability, Environmental Health, Public Safety, Agriculture, Natural Resources, Environment, Other Policy Issues, Climate Change, Public Policy, Government, Water, Biodiversity, United Nations, Fresh water, JBS, CIO, Food, Lazard, GHG, Farm, Environment, COP27, Nitrogen, Egg, ESG, Sunner (surname), FAIRR, Climate, Aquaculture, Disclosure, Nutrient, Strategic sustainable investing, Meat, Forest, Tyson, Phosphorus, Livestock, Food and Agriculture Organization, Nature, First Nations in Ontario, Global biodiversity, WH Group, River, Farmer, Climate change, Coller Capital, Risk, Animal husbandry, Renewable energy, Agriculture, COP15, Index, Jeremy Coller

The world will gather in Montreal tomorrow to discuss a Paris Agreement for Nature (COP15) including a set of proposed targets to halt and reverse global biodiversity loss.

Key Points: 
  • The world will gather in Montreal tomorrow to discuss a Paris Agreement for Nature (COP15) including a set of proposed targets to halt and reverse global biodiversity loss.
  • However, new data from FAIRR today shows the worlds biggest meat and dairy producers are currently unprepared to meet targets expected in such a deal.
  • Jeremy Coller, Chair of FAIRR initiative and CIO of Coller Capital, said,
    From rainforests to rivers, meat & dairy producers are failing to manage their biodiversity impacts.
  • Investors are focused on material financial risks for companies, and a global agreement on nature at COP15 would see the intensive animal agriculture industry face increased regulatory, legal, tax and reputational risks.

HAUS LABS BY LADY GAGA LAUNCHES A CLEAN, CUTTING EDGE LONGWEAR FOUNDATION INFUSED WITH 20+ SKINCARE INGREDIENTS, IN 51 SHADES + 2 ADDITIONAL INNOVATIVE COMPLEXION PRODUCTS

Retrieved on: 
Thursday, September 8, 2022
Product innovation, Research, Arnica, CLEAN, Jeremy Coller, TikTok, MAC Cosmetics, Sephora, USD, Pressure, SVP, Skin, Senior, Science, Innovation, Animation, MAC, Color, Cosmetics, Mental health, Face, Table, Aluminium, Massage, Development, Research and development, Merchandising

Haus Labs is trying to revolutionize the way you think about clean, supercharged artistry in an everyday foundation and powder.

Key Points: 
  • Haus Labs is trying to revolutionize the way you think about clean, supercharged artistry in an everyday foundation and powder.
  • I am so excited about the Triclone Skin Tech Foundation that is in 51 shades across 6 color families based on skin's depth and undertones.
  • "Lady Gaga, Founder of Haus Labs
    "After two years in the making, our Triclone Skin Tech Foundation and Bio-Blurring Loose Setting Powder are finally ready for launch.
  • "-Sarah Tanno, Global Artistry Director, Haus Labs
    Complimenting the Haus Labs complexion arsenal is theHaus Labs Foundation Brush.

Tevard Biosciences licenses mRNA Amplifier technology from Johns Hopkins University

Retrieved on: 
Thursday, March 31, 2022
People, Heart, Mike Hopkins (basketball), Johns Hopkins University, Muscular dystrophy, Silencer (firearm), Lists of diseases, Father, Oligonucleotide, Biotechnology, RNA transfection, Amplifier, Bloomberg, Dravet syndrome, CEO, RNA, Molecular biology, Johns Hopkins School of Medicine, Technology, Gene editing, Haploinsufficiency, Jeremy Coller, Doctor of Philosophy, Mutation, Gene, Degenerative disease, Bloomberg Distinguished Professorships, SAB, Department, Genetics, Protein, Whitehead Institute, MIT, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Tevard Biosciences, the pioneer of tRNA-based treatments for severe genetic diseases, today announced an agreement to exclusively license "mRNA Amplifier" technology from the Johns Hopkins University. The technology will help form the basis of Tevard's third platform for addressing diseases in which a mutation has caused a reduction in or loss of a vital protein.

Key Points: 
  • New platform provides additional avenue for treating severe genetic diseases, joins Tevard's tRNA-based platforms in broadly applicable suite of technologies
    CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Tevard Biosciences , the pioneer of tRNA-based treatments for severe genetic diseases, today announced an agreement to exclusively license "mRNA Amplifier" technology from the Johns Hopkins University.
  • The technology will help form the basis of Tevard's third platform for addressing diseases in which a mutation has caused a reduction in or loss of a vital protein.
  • While the company's first two platforms employ RNA-based molecules called tRNAs, the new mRNA Amplifier platform is based around specially engineered proteins.
  • Tevard Biosciences is pioneering mRNA-modulating therapies to cure a broad range of genetic diseases.

District Ventures Capital Adds to Senior Ranks with Appointment of Jeremy Daveau

Retrieved on: 
Tuesday, September 7, 2021

Operating Partner Brings Wealth of Leadership Experience in Sales, Marketing, Supply Chain

Key Points: 
  • Operating Partner Brings Wealth of Leadership Experience in Sales, Marketing, Supply Chain
    TORONTO, Sept. 7, 2021 /CNW/ - Arlene Dickinson, General Partner of District Ventures Capital is pleased to announce the appointment of Jeremy Daveau as Operating Partner.
  • Mr.Daveauwill be accountable for accelerating the business growth and the financial performance of District Venture's entire investment portfolio of companies.
  • Prior to joining District Ventures Capital, Mr. Daveau was the President and General Manager of Mars Inc. in Canada.
  • District Ventures Capital is a venture capital fund investing in innovative companies in the food & beverage and health & wellness sectors.

FAIRR names Israel's Mileutis as a leader in combating resistance to antibiotics

Retrieved on: 
Monday, August 16, 2021
Health, GMO, GHG, Human, Public health, Awareness, Milk, Research report, Environment, World Health Organization, CEO, Greenhouse gas, ESG, PIMCO, Food, Mastitis, Lactation, Death, COVID-19, R, Fidelity, Risk, FDA, Marketing, NESS, World, Animal, Montbéliarde, European Commissioner, FAIRR, Hormone, Lead, Jeremy Coller, Veterinarian, Bacteria, Farmer, AMR, Pharmaceutical industry, Agriculture

Antimicrobial resistance (AMR) is one of the top 10 global public health threats facing humanity , according to the World Health Organization.

Key Points: 
  • Antimicrobial resistance (AMR) is one of the top 10 global public health threats facing humanity , according to the World Health Organization.
  • The more we use antibiotics, the more chances bacteria will become resistant to them.
  • This means that antibiotics will not work as well when we need them in the future.
  • The FAIRR report chose to profile Mileutis as a company which brings an alternative to the widespread use of antibiotics in the animal health sector.